Cadila Healthcare is currently trading at Rs. 877.50, up by 3.85 points or 0.44% from its previous closing of Rs. 873.65 on the NSE.
The scrip opened at Rs. 877.00 and has touched a high and low of Rs. 885.95 and Rs. 870.00 respectively. So far 33,947 shares were traded on the counter.
The NSE group stock of face value Rs. 5 has touched a 52 week high of Rs. 982.70 on 19-Jul-2011 and a 52 week low of Rs. 620.00 on 25-Jan-2012.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.51% and 8.70% respectively.
Cadila Healthcare, a global pharmaceutical company, and Zydus Pharmaceuticals (USA, a leading generic pharmaceutical company in the United States, have entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.
Under the settlement and license agreement, Cadila Healthcare and Zydus Pharmaceuticals (USA), have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United States under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon’s patents are not infringed, invalid or unenforceable, or earlier under certain circumstances.
Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1689.00 |
| Dr. Reddys Lab | 1219.00 |
| Cipla | 1232.20 |
| Zydus Lifesciences | 939.65 |
| Lupin | 2327.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: